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public databases information and clinical expert panel. The target population was
a birth cohort in São Paulo followed for 5 years (598,474). The vaccination coverage
rate was 90%, considering a four-dose schedule for 10-valent and tree-dose sched-
ule for PCV13 as suggested by international guides. São Paulo costs and disease
data was obtained from national official databases. A mandatory discounted price
to the government, calculated by the ex-factory price minus 24.38% was considered
to PCV13 and 10-valent. Costs and benefits were discounted at 5% annually. Out-
comes were expressed as life years gained(LYG), deaths and number of disease
cases avoided. Only the direct effect of vaccination and direct medical costs were
considered. RESULTS: The analysis showed higher clinical benefits and lower
costs for PCV13 prophylaxis; reduction of 7 deaths, 488 LYG and 17 cases of
disease (sepsis and meningitis) and savings of BRL70,097,844(USD43,909,950) in
5 years. The total costs with events and vaccines were
BRL113,902,160(USD72,576,883) and BRL137,914,893(USD87,877,465), respec-
tively, for PCV13; and BRL113,999,789(USD71,410,542) and
BRL207,915,109(USD130,239,983) for 10-valent. CONCLUSIONS: This study dem-
onstrated that incorporating PCV13 in pediatric immunization routine results in
reduction on mortality and morbidity with lower expected cost for São Paulo state
healthcare system, showing the dominance of PCV13 regarding 10-valent.
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OBJECTIVES: Invasive aspergilosis (IA) is a mycotic disease produce by Aspergillus
sp and represents the second leading cause of invasive fungal infections. The mor-
tality rate is about 50%. The aim of this study was to assess the cost-effectiveness
(CE) of voriconazol, anfotericine B and caspofungin as first line treatments for IA
adult patients in Panama, from the healthcare payer’s perspective. METHODS: A
decision-tree model was used to compare costs and effectiveness of anfotericine B
(comparator), caspofungin and voriconazol for a cohort of patients with IA. Effec-
tiveness measures were: clinical success rates, mortality rates, intensive care unit
(ICU) length of stay (LOS), hospital ward LOS and overall costs. Effectiveness and
epidemiologic data were collected from published literature. Local costs (2011 US$)
were obtained from Panama=s Social Security and Hospital Oncológico Nacional
official databases. The model used a 12-week time horizon and only direct medical
costs were considered. Monte Carlo probabilistic sensitivity analysis (PSA) was
constructed. RESULTS: Results showed voriconazol as the most effective and least
expensive option for IA. Clinical success rate was higher with voriconazol (56.6%)
compared with anfotericine B (36.4%) and caspofungin (34.2%). Mortality rates
were: 34.1% with voriconazol, 50.9% with anfotericine B and 44.7% with caspofun-
gin. Average ICU LOSs was 7.59 days with voriconazol and 9.94 and 9.81 days with
anfotericine B and caspofungin, respectively. Voriconazol also obtained the short-
est ward LOS (15.96 days). Overall medical costs were $13,100 with voriconazol,
$17,347 with anfotericine B and $13,716 with caspofungin. CE analyses showed
voriconazol as the dominant strategy. Acceptability curves showed that voricona-
zol would be cost-effective within 3 GDP per capita threshold. PSA outcomes
support the robustness of these findings. CONCLUSIONS: This is the first CE study
for IA developed in Panamá. Voriconazol resulted as the cost-saving option for
treating IA patients in the Panamanian clinical context.
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OBJECTIVES: The aim of this study is to analyze the cost-effectiveness over 6-year
duration of first line telbivudine and lamivudine treatment in HBeAg-positive
chronic hepatitis B patients with low viral load at baseline in line with the Turkish
reimbursement guideline for oral CHB therapies. METHODS: Using a decision an-
alytical model, cost-effectiveness of telbivudine was evaluated versus lamivudine
in first-line use for HBeAg-positive patients with baseline HBV DNA levels9 log10
copies/mL in Turkish healthcare setting from National Payer’s perspective in ac-
cordance with the local reimbursement guideline for oral CHB treatments based on
roadmap concept. Primary measure of effectiveness was undetectable HBV DNA
level by polymerase chain reaction (PCR) assay at model duration, while costs
included only cost of oral CHB drugs incurred by the Payer. Probabilities of PCR
negativity and resistance rates used in the model are derived from telbivudine’s
head-to-head study versus lamivudine subgroup analyses outcomes for week 24
and 104; and from respective pivotal clinical studies for second line treatments.
RESULTS: In the CE model, total oral CHB treatment cost per HBeAg-positive pa-
tient treated with lamivudine and telbivudine arm over 6 years was estimated to be
12,873€ and 11,435€ respectively. Percentage of patients remaining on lamivudine
at model duration was 23%, while 50% on telbivudine. The average cost-effective-
ness ratio, cost per successfully treated HBeAg-positive patient at year 6, was cal-
culated as 15,362€ for the lamivudine arm and 13,053€ for the telbivudine arm
(difference is 2,309€), and the incremental cost-effectiveness ratio was -37,859€.
CONCLUSIONS: First line CHB treatment with telbivudine in HBeAg-positive pa-
tients has been demonstrated as a dominant cost-effective option than lamivudine
in the Turkish healthcare setting. Although telbivudine has higher reimbursement
price, it has been offset by superior efficacy compared to lamivudine in positive
patients with baseline serum HBV DNA levels9 log10 copies/mL and less need for
more costly second line treatments.
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OBJECTIVES: To estimate the cost of virologic response at week 48 of treatment
with etravirine (ETV), raltegravir (RAL) and maraviroc (MAV) for multi-experienced
patients with 2 or more active drugs in the optimized background therapy (OBT) in
the Brazilian National AIDS Program. METHODS: Treatment regimens of ETV and
RAL were defined by the Brazilian national guidelines. Regimens with MAV were
based in the same principles, although the drug is not yet reimbursed. Patients not
achieving virologic response followed onto subsequent rescue treatments, defined
by the guidelines. Re-treatment was not allowed. Treatment costs included cost of
medication as published on the government website. The cost of MAV was defined
by law. The number of multi-experienced patients receiving treatment was based
on the dispensed capsules of RAL in the last 48 weeks. Virologic response was
gathered from the phase III clinical trials of ETV, MAR and RAL, at week 48 for
patients with two active drugs in the OBT defined by phenotypic susceptibility.
RESULTS: The average cost of treatment at week 48 for multi-experienced patients
with at least 2 active drugs in the OBT was R$ 27,243.14 with ETV, compared with R$
27,702.91 with RAL, and R$ 31,220.72 with MAR. Given 5,627 multi-experienced
patients received treatment, 862 patients failed with MAV, 544 failed treatment
with RAL compared to 337 failed patients with ETV. For one third of the cohort
(1.875), the total cost of treatment was R$ 58,565,276 for MAV, R$ 51,966,391 for RAL,
and R$ 51,103,946 for ETV. CONCLUSIONS: Despite similar treatment costs, treat-
ment with ETV compared to RAL and MAV is a more economic option for the
treatment of multi-experienced patients with at least two active drugs in the OBT.
At week 48, treatment with RAL and MAV was on average 2% and 15% more expen-
sive compared to ETV, respectively.
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OBJECTIVES: To develop a cost-effectiveness analysis of a multidisciplinary sup-
port program (MSP) versus the conventional approach in the Hepatitis C (HC)
treatment. METHODS: A total of 278 mono-infected naive HC patients were in-
cluded: 131 in the MSP group and 147 patients were conventionally controlled
(control group). All patients were treated with Peg-IFN-alfa-2a/ribavirin. The MSP
team not only included hepatologists and nurses, but also, pharmacists, psychol-
ogists and assistants. Standard patient education, open and flexible visits sched-
uling, continued psychiatric evaluation and active medication control were carried
out in the MSP. Treatment adherence, sustained virological response (SVR), and
health resources use were evaluated. A Markov model for a lifetime horizon with
seven health states and from the Spanish NHS perspective was developed. Tran-
sition probabilities and health states utilities were obtained from published liter-
ature. Costs were obtained from the Catalogue of Medicinal Products and from
Spanish studies and databases (€-2010). 3.5% annual discount for costs and out-
comes was applied. RESULTS: In the MSP group treatment compliance was higher
than in the control group (94.6% vs 78.9%, p0.0001). SVR was higher in the MSP
group than in controls for all genotypes (77.1% vs. 61.9%, p0.006), G-1/4 (67.7% vs
48.9%, p0.02), and G-2/3 (87.7% vs. 81.4%, NS). For all genotypes, the cost per
patient (including cost of drugs, health professionals and disease long-term com-
plications) was €13,319 in MSP group and €16,184 in control group, furthermore,
MSP group resulted more QALYs than controls (16.317 vs. 15.814), being MSP dom-
inant (more effective, with lower costs) compared with the conventional approach.
The MSP program was also dominant in G-1/4 patients (saving €2476, increasing
0.622 QALYs/patient) and G-2/3 (saving €1417, gaining 0.208 QALYs/patient). Re-
sults were stable for 95% CI of drug doses. CONCLUSIONS: HC treatment with
Peg-IFN-alfa-2a/ribavirin in a MSP improves the compliance and is a cost-effective
strategy compared with the conventional approach.
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OBJECTIVES: In 2010, there were more than 1500 illness related to Streptococcus
pneumonia infections in pediatric population under 2 years old in Panamá. Cur-
rently, in Panamá, Prevenar 7 is the anti-pneumococcal vaccine (PCV) used. The
aim of this study was to estimate the cost-effectiveness and cost-utility of immu-
nization strategies based on pneumococcal conjugated vaccines (PCVs) in Panamá,
from an institutional perspective. METHODS: A decision tree steady state model
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